Axsome Therapeutics, Inc. AXSM 深 沪
等待开盘 06-25 09:30:00 美东时间
237.92
-4.050
-1.67%
华盛通- 最 高246.76
- 今 开245.60
- 成交量 104.12万股
- 最 低 236.44
- 昨 收 241.97
- 总市值 122.43亿
- 52周最高 260.19
- 市盈率 静 --
- 换手率 2.02%
- 52周最低 96.09
- 委 比 0.00%
- 总股本 5145.98万
- 历史最高 260.19
- 量 比 1.27
- 振 幅 4.26%
- 历史最低 1.94
- 每 手 1
- 风险率 41.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UPDATE 2-Definium's LSD-based depression pill delivers strong late-stage results, shares surge
UPDATE 2-Definium's LSD-based depression pill delivers strong late-stage results, shares surge Updates share movement, adds analyst comment 6 and 7, background throughout By Kamal Choudhury June 22 (Reuters) - Definium Therapeutics DFTX.O said a single dose of its LSD-based experimental pill signifi
06-22 19:11
美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
Axsome to Present New Sleep Disorder Data at SLEEP 2026, To Highlight AXS-12 and Solriamfetol Data for Narcolepsy and OSA
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data on AXS-12 and solriamfetol at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societie...
06-15 19:10
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics announced new data presentations on AXS-12 and solriamfetol at SLEEP 2026, focusing on narcolepsy and excessive daytime sleepiness. Three posters highlight cognitive outcomes, multi-dimensional analysis, and symptom burden in narcolepsy patients. The event took place June 14-17, 2026, in Baltimore.
06-15 11:00
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle June 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arthur J. Gallagher & Co, Datadog and Oracle on Thursday. HIGHLIGHTS * Arthur J. Gallagher & Co. AJG
06-11 15:59
Axsome secures long-term U.S. exclusivity for SUNOSI
The latest announcement is out from Axsome Therapeutics ( ($AXSM) ). On June 3,...
06-03 21:33
Axsome Therapeutics Resolves All Patent Litigation Related To Axsome's Product SUNOSI
Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has resolved all patent litigation
06-03 19:07
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
Axsome Therapeutics解决了与SUNOSI相关的所有专利诉讼，与唯一的首仿药申请公司达成和解协议。根据协议，五家公司将在2040年获得销售仿制药的权利，具体时间取决于是否获得儿科独占权。Axsome已将和解协议提交给美国联邦贸易委员会和司法部审查。
06-03 11:00
William Blair updates its Conviction List
William Blair has updated its Conviction List of stock picks for June. Analysts added Cloudflare (NET), Fastenal (FAST) and Ethos Technologies (LIFE), while removing Guardant Health (GH), AAON (AAON) ...
06-02 17:19
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
Axsome Therapeutics announced new AUVELITY® data presentations at the ASCP 2026 Annual Meeting in Miami, focusing on major depressive disorder, anxious distress, and real-world outcomes. Additional research on Solriamfetol's effects in obstructive sleep apnea was also presented. The company aims to advance CNS disorder treatments through innovative products.
05-26 11:00
